










SUBSTANCJE CZYNNE W LECZENIU:

Multiple myeloma and plasma cell neoplasms

Nazwa substancji czynnej	Czy występuje w standardzie ESMO?	Status refundacji	Dodatkowe informacje
Daratumumab		Reimbursement with restrictions	<p>Daratumumab is indicated: - in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. - as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. - in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/darzalex-epar-product-information_en.pdf</p> <p>Program lekowy: https://www.gov.pl/web/zdrowie/obw-ministra-zdrowia-z-dnia-20-grudnia-2019-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywniowego-oraz-wyrobow-medycznych-na-1-stycznia-2020-r</p>
Elotuzumab		No reimbursement	<p>Elotuzumab is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/empliciti-epar-product-information_en.pdf</p>

Nazwa substancji czynnej	Czy występuje w standardzie ESMO?	Status refundacji	Dodatkowe informacje
Panobinostat		No reimbursement	<p>Panobinostat, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/farydak-epar-product-information_en.pdf</p>
Pomalidomide		Reimbursement with restrictions	<p>Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/imnovid-epar-product-information_en.pdf</p> <p>Program lekowy: https://www.gov.pl/web/zdrowie/obw-ministra-zdrowia-z-dnia-20-grudnia-2019-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywniowego-oraz-wyrobow-medycznych-na-1-stycznia-2020-r</p>
Carfilzomib		Reimbursement with restrictions	<p>Carfilzomib in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/kyprolis-epar-product-information_en.pdf</p> <p>Program lekowy: https://www.gov.pl/web/zdrowie/obw-ministra-zdrowia-z-dnia-20-grudnia-2019-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywniowego-oraz-wyrobow-medycznych-na-1-stycznia-2020-r</p>

Nazwa substancji czynnej	Czy występuje w standardzie ESMO?	Status refundacji	Dodatkowe informacje
Ixazomib		No reimbursement	<p>Ixazomib in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/ninlaro-epar-product-information_en.pdf</p> <p>Lenalidomide as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide as combination therapy is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/revlimid-epar-product-information_en.pdf</p> <p>Program lekowy: https://www.gov.pl/web/zdrowie/obw-ministra-zdrowia-z-dnia-20-grudnia-2019-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywniowego-oraz-wyrobow-medycznych-na-1-stycznia-2020-r</p>
Lenalidomide		Reimbursement with restrictions	<p>Thalidomide in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/thalidomide-celgene-epar-product-information_en.pdf</p>
Thalidomide		No reimbursement	<p>Thalidomide in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/thalidomide-celgene-epar-product-information_en.pdf</p>

Nazwa substancji czynnej	Czy występuje w standardzie ESMO?	Status refundacji	Dodatkowe informacje
Dexamethasone		Full reimbursement	<p>Dexamethasone is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.</p> <p>EPAR/ChPL: https://www.ema.europa.eu/document/information/neofordex-epar-product-information_en.pdf</p> <p>Program lekowy: https://www.gov.pl/web/zdrowie/obw-ministra-zdrowia-z-dnia-20-grudnia-2019-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywniowego-oraz-wyrobow-medycznych-na-1-stycznia-2020-r</p>